Prolong Completes Enrolling Patients in Phase 2 Trial of Sickle Cell Disease Therapy Sanguinate by Prolong Pharma | Dec 1, 2017 | News
Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting by Prolong Pharma | Dec 1, 2017 | News
